anti-ILT3 CAR T-cell therapy (Carbiogene Therapeutics)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-ILT3 CAR T-cell therapy (Carbiogene Therapeutics)
Drug Alias Nameanti-LILRB4 CAR T-cell therapy (Carbiogene Therapeutics)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionLeukocyte immunoglobulin-like receptor subfamily B member 4 modulators
TargetsLeukocyte immunoglobulin-like receptor subfamily B member 4
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCarbiogene Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCarbiogene Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A